{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"Decrease to =<35"},{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}],"title":"Change to Normal or to No Change"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"Increase to >=38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"Temperature was measured after resting for at least 5 minutes. The abnormal ranges for body temperature were (\\<=35 degrees Celsius or \\>=38 degrees Celsius). Baseline was defined as the latest pre-dose assessment within 21 days prior to first dose with a non-missing value, including those from unscheduled visits.","groups":[{"description":"Participants with Relapsed or Refractory Multiple Myeloma (RRMM) received belantamab mafodotin as 2.5 milligram (mg)/kilogram (kg) dose via intravenous (IV) infusion on Day 1 of every 21-day cycle (Q3W) maximum up to disease progression.","id":"OG000","title":"Main Study - Part 1: Belantamab Mafodotin 2.5 Milligram/ Kilogram (mg/kg)"},{"description":"Participants with RRMM received belantamab mafodotin as dose of 3.4 mg/kg via IV infusion on Day 1 of every 21-day cycle (Q3W) maximum up to disease progression.","id":"OG001","title":"Main Study - Part 1: Belantamab Mafodotin 3.4 mg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated population.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and up to approximately 141 weeks","title":"Part 1: Number of Participants With Worst-case Change Post-baseline in Vital Sign Parameters: Temperature","type":"PRIMARY","unitOfMeasure":"Participants"}